First-line treatment of advanced acral melanoma with the PD-1 inhibitor toripalimab (Loqtorzi) resulted in a small but ...

A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.

Piqray plus Faslodex significantly improved PFS in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast ...

Please provide your email address to receive an email when new articles are posted on . Patients who achieved undetectable measurable residual disease had a 72% reduced risk for disease progression or ...

The 36-month PFS rate for patients with del (17p) and/or TP53 mutation was 87% and for patients without del (17p) and TP53 mutation was 89%. The safety profile of BRUKINSA plus venetoclax was ...

Intensity-modulated proton therapy (IMPT) improves overall survival (OS) and reduces high-grade toxicity compared with intensity-modulated radiation ...

A low prognostic nutritional index may indicate a reduced response to ICIs due to diminished hepatic function and systemic inflammation.

Varegacestat, an investigational gamma secretase inhibitor (GSI), delivered clinically meaningful improvements in efficacy outcomes vs placebo in patients with progressing desmoid tumors, according to ...

Please provide your email address to receive an email when new articles are posted on . Minimal residual disease status appeared prognostic for PFS at three specific time points for patients with ...

Italian investigators sought to determine if combining R-CHOP plus ibrutinib followed by ibrutinib maintenance improved PFS in treatment-naive patients aged 65 years and younger with high-risk ABC ...